Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice by Ruiz Díaz, Miguel Ángel et al.
© 2015 Ruiz et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Drug Design, Development and Therapy 2015:9 4329–4340
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
4329
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/DDDT.S88238
Modeling the longitudinal latent effect of pregabalin 
on self-reported changes in sleep disturbances in  
outpatients with generalized anxiety disorder 
managed in routine clinical practice
Miguel a ruiz1
enrique Álvarez2
Jose l carrasco3
José M Olivares4
María Pérez5
Javier rejas6
1Department of Methodology, school 
of Psychology, Universidad autónoma 
de Madrid, Madrid, 2Department of 
Psychiatry, hospital de la santa creu 
i san Pau, Barcelona, 3Department 
of Psychiatry, hospital clínico san 
carlos, Madrid, 4Department of 
Psychiatry, hospital Meixoeiro, 
complejo hospitalario Universitario, 
Vigo, 5Medical Department, Pfizer, 
s.l.U., alcobendas, Madrid, 6health 
economics and Outcomes research 
Department, Pfizer, s.l.U., alcobendas, 
Madrid, spain
Background: Anxiety disorders are among the most common psychiatric illnesses, with 
generalized anxiety disorder (GAD) being one of the most common. Sleep disturbances are highly 
prevalent in GAD patients. While treatment with pregabalin has been found to be associated with 
significant improvement in GAD-related sleep disturbance across many controlled clinical trials, 
mediational analysis has suggested that a substantial portion of this effect could be the result 
of a direct effect of pregabalin. Thus, the objective of this study was to model the longitudinal 
latent effect of pregabalin or usual care (UC) therapies on changes in sleep in outpatients with 
GAD under routine clinical practice.
Methods: Male and female GAD outpatients, aged 18 years or above, from a 6-month 
prospective noninterventional trial were analyzed. Direct and indirect effects of either pregabalin 
or UC changes in anxiety symptoms (assessed with Hamilton Anxiety Scale) and sleep distur-
bances (assessed with Medical Outcomes Study-Sleep Scale [MOS-S]) were estimated by a 
conditional latent curve model applying structural equation modeling.
Results: A total of 1,546 pregabalin-naïve patients were analyzed, 984 receiving pregabalin 
and 562 UC. Both symptoms of anxiety and sleep disturbances were significantly improved in 
both groups, with higher mean (95% confidence interval) score reductions in subjects receiving 
pregabalin: -15.9 (-15.2; -16.6) vs -14.5 (-13.5; -15.5), P=0.027, in Hamilton Anxiety Scale; 
and -29.7 (-28.1; -31.3) vs -24.0 (-21.6; -26.4), P0.001, in MOS-S. The conditional latent 
curve model showed that the pregabalin effect on sleep disturbances was significant (γ =-3.99, 
P0.001), after discounting the effect on reduction in anxiety symptoms. A mediation model 
showed that 70% of the direct effect of pregabalin on sleep remained after discounting the 
mediated effect of anxiety improvement.
Conclusion: A substantial proportion of the incremental improvements in anxiety-related 
sleep disturbances with pregabalin vs UC were explained by its direct effect, not mediated by 
improvements in anxiety symptoms.
Keywords: latent curve analysis, pregabalin, usual care, generalized anxiety disorders, sleep 
disturbances
Introduction
Anxiety disorders are among the most common psychiatric illnesses, with generalized 
anxiety disorder (GAD) being one of the most common in primary care.1–3 Lifetime 
prevalence of GAD has been estimated to be 2%–3% in Europe and near 6% in the 
United States.1,4,5 GAD is a chronic disorder characterized mainly by pathological 
worry, which presents with a variety of somatic and psychological symptoms.6 It has 
correspondence: Miguel a ruiz
Facultad de Psicología, Universidad 
autónoma de Madrid, calle ivan  
Pavlov 6, 28049 Madrid, spain
Tel +34 91 497 5211
Fax +34 91 497 5215
email miguel.ruiz@uam.es 
Journal name: Drug Design, Development and Therapy
Article Designation: Original Research
Year: 2015
Volume: 9
Running head verso: Ruiz et al
Running head recto: Modeling pregabalin on self-reported changes in sleep disturbances
DOI: http://dx.doi.org/10.2147/DDDT.S88238
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4330
ruiz et al
been found that GAD has a great impact on health-related 
quality of life, and especially on sleep. It has also been 
found to have an impact on patient functionality, causing 
substantial disability.1
The pharmacological management of GAD is centered 
mainly on anxiolytic drugs (ie, benzodiazepines), either in 
monotherapy or in combination.7 However, benzodiazepines 
have limited efficacy in relieving comorbid depressive symp-
toms and have undesirable effects, and the general guidance 
is that benzodiazepines should be restricted to short-term 
use.8–11 Despite this, usual care (UC) practice including 
these drugs is still widespread.8–11 As they are recommended, 
effective treatments that may be used on a long-term basis 
include selective-serotonin reuptake inhibitors (SSRIs) 
and selective serotonin-norepinephrine reuptake inhibitors 
(SNRIs), and many patients with GAD are receiving such 
medicines on a daily basis, either as monotherapy or as an 
add-on treatment.11–14 Pregabalin has also shown to be effec-
tive in the reduction of the psychic and somatic symptoms 
of GAD,15–17 and has therefore been recommended, along 
with other anxiolytic drugs (ie, SSRI, SNRI, etc.), as a first-
choice treatment in this disorder.11 In addition, pregabalin has 
shown a beneficial effect on sleep and sleep architecture that 
differs from that of benzodiazepines in healthy volunteers; 
this effect is characterized by the enhancement of slow-wave 
sleep (SWS).18,19 Polysomnography revealed fewer awaken-
ings, more time spent in SWS, and less time spent in stage 1 
sleep, suggesting that pregabalin consolidates fragmented 
sleep and increases depth of sleep in some health conditions 
(fibromyalgia, neuropathic pain, partial epilepsy, etc.).19 
Nevertheless, polysomnography studies have not been car-
ried out yet in patients with GAD. Therefore, the exact rela-
tionship between SWS and GAD symptom recovery is still 
unknown. Pregabalin has also been shown to improve sleep 
disturbances in patients with epilepsy and subjects with a 
variety of chronic pain conditions including fibromyalgia.20,21 
In a recent observational benzodiazepine-withdrawal study 
with pregabalin,22 patients who still exhibited significant 
anxiety symptoms at the end of the study showed a significant 
improvement in their self-reported sleep quality as assessed 
with the Medical Outcomes Study-Sleep Scale [MOS-S]).23 
As was also recently reported by Bollu et al24 this would 
suggest that the effect of pregabalin on these patients’ sleep 
quality was partly independent of its anxiety-symptom 
amelioration effect. The moderate correlation between the 
improvement in sleep quality and the improvement in illness 
severity could be interpreted in the same way.25 However, it 
is important to highlight that results from clinical trials could 
differ from results from daily clinical practice.26 In clinical 
trials, patients are selected according to restrictive criteria 
that usually exclude patients receiving several treatments, 
which is not necessarily the case for the many GAD patients 
treated in real clinical practice.17
While treatment with pregabalin has been found to be 
associated with significant improvement in GAD-related 
sleep disturbance across seven placebo-controlled clinical 
trials,27 mediational analysis has suggested that a substantial 
portion of this effect could be the result of a direct effect of 
pregabalin.24 A recent review of the effect of pregabalin on 
sleep disturbance indicates that this drug has a direct effect 
on sleep that is different from its analgesic, anxiolytic, and 
anticonvulsant effects,28 and that polysomnographic data 
reveal that pregabalin primarily affects sleep maintenance.19 
To our knowledge, no one to date has explored whether such 
a direct effect of pregabalin on sleep disturbances, not medi-
ated through prior reduction in anxiety symptom severity, 
remains when compared with UC treatments in routine clini-
cal practice. Thus, the aim of this study was to carry out a 
mediation path analysis to test the effect of pregabalin on 
the reduction in self-reported anxiety-related sleep problems 
due to the improvement of GAD symptoms when added to 
the management of community-treated patients with GAD. 
A stand-alone estimation of mediation for adding pregabalin 
effects was carried out, in addition to a comparison against 
UC anxiolytic therapies.
Methods
study design
A post-hoc analysis was carried out on the existing data from 
outpatients with GAD diagnosed according to the DSM-
IV-TR definition gathered from a 6-month, multicenter, pro-
spective noninterventional trial (the ADAN [Amplification of 
Definition of Anxiety] study).29 In brief, the ADAN study was 
designed to determine the effect of abridging the DSM-IV 
criteria for GAD, and the study protocol was approved by the 
local ethics committee of the Hospital Clínico de San Carlos 
in Madrid. It was conducted according to the Declaration 
of Helsinki for medical research in the human being. The 
study was carried out between October 2007 and January 
2009 in outpatient mental health clinics all over Spain. Due 
to the noninterventional design of the study, only three visits 
(baseline, 3, and 6 months) were planned.
study population
In the ADAN study, trained psychiatrists with at least 
5 years’ experience in mental illness diagnosis were asked to 
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select consecutive, newly-diagnosed GAD patients accord-
ing to DSM-IV criteria (Mini International Neuropsychiatric 
Interview was applied) and the so-called abridged criteria.29 
Male and female patients aged 18 or above who had provided 
their written informed consent to participate in the study 
and who showed a poor/insufficient response to previous 
anxiolytic therapy were considered eligible. Poor/insufficient 
response to previous anxiolytic therapy was defined, in this 
post-hoc analysis, according to Rickels et al30 as persistent 
anxiety symptoms or showing a suboptimal response after a 
course of a standard-dose regimen with any drug indicated 
for GAD, alone or in combination, for at least 6 months 
prior to the baseline study visit. Persistent symptoms or 
suboptimal response was considered when patients claiming 
to suffer from anxiety symptoms scored 16 points on the 
Hamilton Anxiety Scale (HAM-A) and 3 on the Clinic 
Global Impression – Severity Scale (CGI-S) at baseline visit. 
Patients unable to understand patient-reported-outcomes 
questionnaires written in Spanish for any reason, including 
receiving drug-based therapies or severe illnesses that in 
the judgment of the participating physicians might interfere 
with the patient’s ability to fill in the questionnaires, were 
excluded from participating in the study.
The post-hoc analysis included here was based on the 
study population mentioned earlier that included outpa-
tients with GAD, as per the DSM-IV definition only, who 
were classified into one of the following treatment groups: 
pregabalin group – patients changing from any treatment at 
baseline (SSRI/SNRI or other anxiolytic drugs) and starting 
on or including pregabalin in their therapy for the following 
6 months of follow-up; or UC treatment group – patients 
changing their prior anxiolytic treatment or adding a new 
anxiolytic other than pregabalin. More detailed information 
on the treatments followed by patients can be found in the 
Results section and in Table 1. No patients included in the 
analysis could have been exposed to pregabalin previously. 
Only patients changing to pregabalin or modifying their prior 
anxiolytic treatment were considered. Those continuing on 
any of the mentioned treatments without any modification 
in their therapy or those previously exposed to pregabalin 
were excluded from the analyses. Patients increasing the 
dose of the prior anxiolytic without adding a new drug were 
also excluded.
Patient-reported outcomes measured during 
the study
At baseline, sociodemographic data, current therapy 
including symptomatic treatments and information on 
psychiatric and medical illnesses were all recorded. At 
3- and 6-month visits, psychiatrists collected data relating 
to patients’ follow-up and current treatments. Functional 
outcome measures were completed at all three visits and 
included the following instruments: the HAM-A,31,32 the 
CGI-S,33 and the MOS-S.23 The HAM-A is a 14-item, inter-
viewer-administered scale formulated as a semistructured 
interview to assess the subject’s level of anxiety. Items are 
scored from 0 (not present) to 3 (severe). The total score 
ranges from 0 to 42 points and can be categorized into 
four severity groups: normal (0–9); mild (10–15); moder-
ate (16–24); or severe (25–42). The MOS-S questionnaire 
is a patient-reported measure consisting of 12 items that 
assess the key constructs of sleep. It is self-administered, 
and patients are asked to recall sleep-related activities over 
the past four weeks. Instrument scoring results in six scales 
or domains: sleep disturbance (4 items); snoring (1 item); 
awakening with shortness of breath or headache (1 item); 
quantity of sleep (1 item); optimal sleep (1 item); sleep 
adequacy (2 items); and daytime somnolence (3 items). 
In addition, two summary index measures that assess sleep 
problems can also be constructed with 6 or 9 items, respec-
tively, to provide composite scores. Both index measures 
are highly correlated. The sleep problems index in this 
article always refers to the 9-item composite measurement 
only. Quantity of sleep is scored as the average number 
of hours slept per night. The other scales and composite 
measurements are scored on a transformed 0–100 metric, 
where higher scores indicate more of the concept being 
assessed.
statistical analysis
For statistical analysis, only patients that fulfilled all inclu-
sion criteria and none of the exclusion criteria listed above 
were included. Descriptive statistics were extracted for the 
continuous variables in the study, including the assessment 
of central tendency and dispersion statistics with their 95% 
confidence intervals when possible. After describing the 
output variables considered in the study, a repeated measures 
analysis of variance (ANOVA) was carried out to interpret 
changes in the patient-reported outcome (PRO) measures 
over time and to assess any differences between treatment 
groups. In a separate analysis, each of the PRO instruments 
(HAM-A and MOS-S) was used as the dependent variable, 
treatment group as a between-groups factor, and time as a 
within-groups factor. Main effects and interaction terms were 
assessed. Bonferroni adjustment was applied for post-hoc 
comparisons when necessary.
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Table 1 sociodemographic variables: overall and by treatment group
Variables Overall Usual care Pregabalin
Total patients (n) 1,546 562 (36.4%) 984 (63.6%)
sex (%)
Female 68 66 69
civil status (%)
single 24 25 23
Married 56 58 57
cohabitation 6 5 6
Widow 5 3 5
Divorced/separated 10 9 10
educational level (%)
illiterate 0.4 0.4 0.4
Functional illiterate 3.8 4.3 2.5
Primary 34.5 33.2 34.6
secondary 21.1 19.1 21.6
graduate 19.9 20.7 20.8
Postgraduate 19.5 21.9 19.0
Occupation (%)
student 1.9 3.0 1.3
employed 52.5 55.2 54.1
long-term disabled 7.3 3.9 7.3
Unemployed 7.6 7.1 7.0
retired 6.1 6.4 4.8
homemaker 22.6 22.5 23.4
Other 2.1 1.8 2.0
age (mean, sD) years 45.48 (12.95) 44.35 (13.48) 45.72 (12.52)
BMi (mean, sD) kg/m2 25.38 (4.17) 25.35 (4.45) 25.37 (4.00)
anxiolytic treatment at baseline (%)a
ssri/snri + benzodiazepine 46.7 42.7 49.0
Benzodiazepine 24.7 30.8 21.2
ssri/snri 6.4 5.9 6.7
ssri/snri + benzodiazepine + antiepileptic 5.8 3.7 6.9
ssri/snri + benzodiazepine + opioid 1.9 2.0 1.8
ssri/snri + antiepileptic 1.0 0.5 1.3
Benzodiazepine + antiepileptic 1.0 1.4 0.7
ssri/snri + benzodiazepine + antiepileptic + opioid 0.5 0.5 0.4
ssri/snri + opioid 0.3 0.4 0.3
Opioid 0.2 0.4 0.1
antiepileptic 0.1 0.2 0
Other possible therapy patterns 11.5 11.6 11.5
Notes: aMost frequent treatment profiles. Antiepileptic drugs may include gabapentin, topiramate, carbamazepine, or lamotrigine. Other possible therapy patterns may 
include any of the following alone or in combination with ssri/snri drugs, benzodiazepines, or antiepileptic: buspirone, trazodone, iMaOs, tricyclic antidepressants, etc.
Abbreviations: BMi, body mass index; iMOa, mono-amino-oxidase inhibitor; sD, standard deviation; snri, serotonin-norepinephrine reuptake inhibitor; ssri, selective 
serotonin reuptake inhibitor.
Latent curve model methodology was used to estimate, 
after adjusting for anxiety reduction, whether differences 
between pregabalin and UC exist in the evolution of sleep 
problems over time. In our work, the latent curve model 
containing time-variant covariates (anxiety levels) and a time-
invariant covariate (treatment group) was considered the most 
adequate procedure to test the hypothesis of this work. Never-
theless, other more frequent and simple models, like repeated 
measures ANOVA, mediation model, and a time-invariant 
conditional latent curve model, were also estimated in order 
to make it easier to interpret results by comparison.
A mediation path-analysis model was estimated using 
a structural equation model.34,35 In the proposed model, the 
treatment administered to patients was considered a dummy 
exogenous variable {x
i
: i=1, 2, …, N}, taking values x
i
 =1 
for pregabalin treatment and x
i
 =0 otherwise. Figure 1 shows 
the estimated model assessing the effect of pregabalin on 
MOS-S scores when HAM-A scores mediate. The model 
estimating the mediated effect of pregabalin on sleep quality 
benefits when considering anxiety changes needs to include 
one exogenous variable (receiving pregabalin or not) and two 
endogenous variables: the change from baseline to month 6 
in sleep quality (y
1i
), which is the dependent variable, and 
the change from baseline to month 6 in anxiety levels (y
2i
), 
which is the mediator variable. Treatment has a direct effect 
on sleep quality (γ
11
) and on anxiety levels (γ
21
), and also a 
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Figure 1 raw maximum likelihood estimates for the mediation model for sleep 
disturbances.
Notes: Boxes represent observed variables, and circles unobserved error variables. 
lines represent regression effects, and the values above them, raw estimated 
regression weights. Values above exogenous variables represent means and 
variances, values above endogenous variables represent means. Mediated effect: γ21 × 
β21 =1.345×1.388=1.867. Δ0–6 anxiety = change in anxiety level from baseline to 
month 6. Δ0–6 sleep = change in sleep problems from baseline to month 6. Pregabalin: 
treatment dummy variable (0= usual care, 1= pregabalin).
mediated effect on sleep quality through anxiety levels (γ
21 
× β
12
). Anxiety level has a direct effect on sleep quality 
(β
21
). The total effect of treatment on sleep quality is the 
simple sum of the direct effect plus the indirect effect. The 
mediation model can be represented by the following set of 
equations: 
 y
1i
 = γ
11
x
1i
 + β
12
y
2i
 + ζ
1i
 (1)
for sleep changes, and
 y
2i
 = γ
21
x
1i
 + ζ
2i
 (2)
for anxiety changes. The proposed set of equations can 
be represented as in Figure 1, replacing variable symbols 
with conceptual labels describing the content of variables. 
If complete mediation exists, the indirect mediated effect 
represented by the product γ
21 
× β
12
 should be significant, and 
the direct effect γ
11
 should equal zero. If partial mediation 
exists, the mediated effect should still be significant, but the 
direct effect γ
11
 should not disappear. Raw effects should be 
considered (and not the standardized values). In order to test 
the significance of the interaction of terms, the Sobel test was 
applied.36,37 The test statistic can be defined as: 
 z = γ
21
β
12
/ 2 2 2 2
12 21
ˆ ˆ( ).γ ββ σ + γ σ  (3)
Since the exogenous variable was not measured on a continu-
ous scale, a bootstrap estimation was also used to estimate 
parameters and standard errors using 1,000 samples.
A latent curve model33 was also estimated using structural 
equation modeling. Given that individual variability (individ-
ual trajectory of PROs over time) will always be present and 
may affect the estimation of the mean trajectory, a multivariate 
approach is preferred, as suggested, in order to obtain better 
estimates of slope standard errors. Moreover, once a random 
effects model had been defined, it was also possible to esti-
mate the effect of covariates on the parameters of the model. 
A null model comparison was estimated first, consisting of 
an unrestricted latent linear trend for the changes in sleep 
symptoms over time (baseline, months 3 and 6) with indi-
vidual random effects on the slope and on the intercept. This 
model was estimated for UC and pregabalin treatment groups 
separately in order to compare parameter estimates with 
those known from the corresponding ANOVAs. Secondly, 
a competing model was estimated establishing pregabalin 
treatment as exogenous predictor (1= pregabalin, 0= usual 
care) of the random slope and intercept. Thirdly, a more 
elaborated model was tested, including anxiety symptoms 
measured at each time point as exogenous variables affecting 
sleep problems acting as covariates. The multilevel model for 
the latent trajectory was based on two different equations. 
At the individual level, the trajectory equation for each patient 
over time was expressed as a linear, time-dependent trend: 
 y
it
 = α
i
 + λ
t
β
i
 + ε
it
, (4)
representing that each patient i={1, …, N} followed an 
individual trajectory over time y
it
 with a random intercept α
i
 
and a random slope β
i
, for case i. The pattern of the trajec-
tory is determined by the λ
t
 constants, which were selected 
for the appropriate pattern. The set of values λ
1 
=0, λ
2 
=0.5, 
and λ
3 
=1 were selected to represent a linear pattern for the 
three repeated measurements in order to scale the estimate 
of the slope as the change from baseline to month 6 (instead 
of the change by time unit). It should be noted that λ
1 
=0, 
which is similar to not drawing the corresponding effect 
arrow in Figure 2. Intercept and slope at the individual level 
can be expressed as deviations from the mean intercept 
and the mean slope, and described using two equations 
(in the unconditional model), one for the random intercept: 
 α
i
 = µα + ζαi (5)
and another for the random slope: 
 β
i
 = µβ + ζβi, (6)
where µα and µβ represent the mean intercept and the mean 
slope, respectively, across all cases, while ζαi and ζβi represent 
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Figure 2 estimated effect of pregabalin treatment on the random slope and intercept of MOs-s over time.
Notes: Boxes represent observed variables, and circles unobserved error variables. straight lines represent regression effects, and the values above them, raw estimated 
regression weights. curved lines represent covariances and values above their estimate. Values above exogenous variables represent means and variances, and values above 
endogenous variables represent means. estimated mean values for the random slope (α) and intercept (β) have been labeled. 
Abbreviations: MOs-s, Medical Outcomes study-sleep scale; sleep0, sleep score at baseline; sleep3, sleep score at month 3; sleep6, sleep score at month 6.
the individual disturbance of mean values. Once the model 
was known to be identified, separate estimates for the mean 
latent intercept and mean slope values were obtained for each 
treatment group. Estimates of the latent curve model were 
compared with those of the repeated measures ANOVAs 
in order to validate the parameter estimates obtained. After 
checking parameter concordance, a restricted latent curve 
model was proposed in which the treatment effect on random 
slope and intercept could be assessed. This baseline model 
was used to compare the mediating effect of controlling for 
anxiety symptoms over the random slope and intercept.
The statistics software packages IBM SPSS Statistics 
version 20 and IBM AMOS version 20 (IBM Corporation, 
Armonk, NY, USA) were used to analyze the data sets.
Results
sample
The ADAN study database included 1,815 patients. Of 
these, 1,546 subjects had complete information about the 
treatments received (both at baseline and during follow-up) 
and fulfilled selection criteria to be included in the analysis. 
Females made up 68%, mean age was 45.5 years (standard 
deviation =13.0), and mean body mass index 25.38 kg/m2 
(standard deviation =4.17). Table 1 shows other sociode-
mographics collected in the study and the most frequent 
treatment profiles before starting the follow-up period by 
treatment group. Patients with no information gathered 
about their treatments, either prior to or during the follow-up 
period, were excluded from the analyses, and 250 patients 
(13.8%) who were already being treated with pregabalin 
were also withdrawn since they were not naïve to the target 
treatment. A total of 19 patients did not have any informa-
tion about their treatments and were discarded. None of the 
treatment patterns (before + during follow-up) were used 
in more than 10% of cases. The most common pattern was 
changing from one SSRI/SNRI plus one benzodiazepine to 
one SSRI/SNRI plus one benzodiazepine plus one antiepi-
leptic (9.7%).
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The pharmacological treatment profiles found in the study 
can be summarized as follows: 14.5% were being treated 
with SSRI/SNRI medication and remained on SSRI/SNRI 
treatment during follow-up, but with different drugs, without 
including pregabalin; 42.3% started the study on SSRI/SNRI 
medication and included or switched to pregabalin during 
follow-up; 21.3% were being treated with medication other 
than SSRI/SNRI or pregabalin and changed to or included 
pregabalin during follow-up; 11% were on medication other 
than SSRI/SNRI or pregabalin and changed to SSRI/SNRI 
during follow-up; 5.8% were on SSRI/SNRI and changed 
to other medication (not SSRI/SNRI or pregabalin) dur-
ing follow-up; and 5.1% were on medication other than 
SSRI/SNRI or pregabalin and remained on other medica-
tion (not SSRI/SNRI or pregabalin) during follow-up. In 
summary, our analysis focuses on those patients changing 
from any treatment at baseline (SSRI/SNRI or other) and 
initiating or including pregabalin treatment during the 
6 month follow-up; this adds up to 984 patients (63.6%). 
Other treatment profiles accounted for 562 (36.4%) patients, 
and these were considered the comparison group. This group 
was labeled the “usual care” (UC) treatment group. A total 
of 36 out of 562 patients (6.4%) had received pregabalin 
before baseline visit in the UC group. Treatment profiles 
were similar in both groups, except for benzodiazepine-alone 
treatment, which was found to be less frequently used in the 
pregabalin group (Table 1, P0.05).
Patient-reported outcomes
Mean anxiety scores, as measured by HAM-A, described 
a descending trend over time at 3 and 6 months (Table 2). 
The term representing the interaction of the time pattern with 
the type of treatment was significant (F=6.6, P=0.002), and 
hence the reduction in anxiety over time should be considered 
different between treatments. The overall difference between 
treatment groups also reached significance (F=4.9, P=0.027), 
representing a smaller score for the anxiety average in the 
pregabalin group. The MOS-S showed a similar descent 
pattern at months 3 and 6 (Table 2). The term representing 
the interaction of the time pattern with the type of treatment 
was also significant (F=15.470, P0.001), and hence the 
reduction in sleep problems over time should be considered 
different between treatments. The general changes in sleep 
problems over time followed a linear pattern (F=1,955.2, 
P0.001), which depicts a continued decrease in sleep 
problems over time, a decrease that plateaus slightly in 
the final time period. Furthermore, the overall difference 
between treatment groups also reached significance (F=16.3, 
P0.001), representing a smaller score for the MOS-Sleep 
overall average in the pregabalin group. All comparisons 
between time point measurements were significant within 
each treatment group (P0.001). While in the pregabalin 
group the improvement in sleep from baseline to month 6 
is -29.7, in the UC group this was smaller, -24.0, repre-
senting a significant difference of 5.689 points favoring the 
pregabalin group (P0.001).
Mediational analysis of the effect of treatment  
on sleep disturbances
Figure 1 shows model estimates when the mediator variable 
representing the change in anxiety level from baseline to 
month 6 (Δ
0–6
 Anxiety = y
2
) mediates the effect of introducing 
pregabalin on reduction in sleep problems (Δ
0–6
 Sleep = y
1
). 
Values above squared variables represent mean changes, 
values close to circled unobserved error variables rep-
resent centered means (0) followed by error variances, 
and values above arrows represent estimated regression 
weights. The first value above the pregabalin variable 
Table 2 Mean values (95% confidence interval) [effect size] at baseline by type of patient-reported outcome for each treatment 
group, differences between treatment at each time measurement, and mean differences from baseline to follow-up visit
Baseline Change at month 3a Change at month 6a F-value significance (df1, df 2)
T t T × t
haM-a 0.027 0.001 0.002
Uc 25.1 (24.4; 25.8) -10.1 (-11.0; -9.2) [1.5]* -14.5 (-15.5; -13.5) [2.0]* (1, 1,299) (2, 2,458) (2, 2,458)
PgB 26.4 (26.0; 26.9) -10.2 (-10.8; -9.7) [1.4]* -15.9 (-16.6; -15.2) [2.3]*
Difference 1.4 (0.5; 2.2) [0.5]** 0.1 (-0.7; 0.9) [0.03] 1.5 (0.5; 2.4) [0.5]**
MOs-s composite score 0.001 0.001 0.001
Uc 46.2 (46.5; 49.8) -16.5 (-18.6; -14.3) [1.0]* -24.0 (-26.4; -21.6) [1.4]* (1, 1,183) (2, 2,366) (2, 2,366)
PgB 54.6 (53.5; 55.7) -20.4 (-21.9; -18.9) [1.3]* -29.7 (-31.3; -28.1) [1.9]*
Difference 6.5 (4.5; 8.4) [1.5]** 4.0 (1.9; 6.0) [0.9]** 5.7 (3.4; 8.0) [1.3]**
Notes: aChange in differences computed as follow-up minus baseline; *P0.001 vs baseline visit; **P0.001 PgB vs Uc.
Abbreviations: haM-a, hamilton anxiety scale; MOs-s, Medical Outcomes study-sleep scale; PgB, pregabalin; T, treatment; t, time; T × t, interaction treatment × time; 
Uc, usual care.
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(0.69) represents the proportion of cases in the pregabalin 
group (pregabalin =1), and the second value, the estimated 
variance for this proportion (0.21=0.69× [1-0.69]). Values 
above squares representing dependent observed variables 
denote variances. Table 3 contains parameter estimates for 
the regression weights, their standard errors, and observed 
significance level for maximum likelihood estimates, along 
with bootstrap standard error estimates (SE), standard error 
estimates for the standard errors (SE-SE), mean parameter 
estimates (Mean), and bias for the parameter estimates 
(Bias) and for the standard errors (SE-Bias). All regression 
estimates were significantly different from 0, and hence 
we were able to assume that a partial mediation effect 
was present. Bootstrap estimates did not differ from those 
obtained by maximum likelihood. Bootstrap standard error 
estimates were slightly smaller, regression weight estimates 
slightly bigger, and significance levels unaltered. The direct 
effect of introducing pregabalin treatment on sleep changes 
was reduced from γ
11
 =6.18 in the model estimating the 
stand-alone direct effect (not shown here) to γ′
11
 =4.314 
in the mediated model (reducing it to 69.7% of its initial 
value). Pregabalin direct effect on anxiety changes con-
veyed a reduction of γ
21
 =1.345 points more than UC, and 
the direct effect of anxiety reduction on sleep improve-
ment was β
12
 =1.388 greater for the pregabalin group. 
Both direct effects result in a combined indirect effect 
of γ
21
 × β
12
 =1.345×1.388=1.867. The sum of the direct 
effect (γ′
11
 =4.314) plus the indirect mediated effect (γ
21
 × 
β
12
 =1.867) adds up to the total effect of 4.314+1.867=6.181, 
which matches the direct not-mediated effect of pregabalin 
treatment on MOS-S changes. The Sobel test produced a 
value of z=2.555 for the mediated effect (γ
21
 × β
12
 =1.867), 
which is significant (P=0.0053).
latent curve analysis on sleep disturbances
Maximum likelihood estimates obtained with the unrestricted 
latent curve model for the mean slope were very close to those 
obtained by repeated measures ANOVA, although new esti-
mates for the standard errors were smaller; hence, estimates 
of confidence intervals were also narrower. For the UC group, 
the ANOVA estimate for the slope was dif. (0–6) =-23.981 
(SE =1.007), while the latent curve estimate was µβ =-24.695 
(SE =0.605). For the pregabalin group, the ANOVA estimate 
for the slope was dif. (0–6) =-29.670 (SE =0.676), while 
the latent curve estimate was µα =-29.993 (SE =0.642). 
The difference in slopes when comparing estimates for the 
pregabalin group and the UC group was Δµβ =-5.298 points 
steeper for the pregabalin group.
The alternative estimate of the difference between treat-
ment groups obtained with the restricted model including 
the effect of treatment (pregabalin) on the random slope and 
intercept was similar (Figure 2). In this model, µβ =-24.695 
(SE =0.885) represents the latent mean slope for the UC 
group, and µα =47.233 (SE =0.675) the latent mean inter-
cept for this treatment group. The estimated increase in the 
random slope due to the inclusion of pregabalin treatment was 
γβ =-5.292 (SE =1.109, P0.001), and the estimated change 
in the random intercept γα =5.652 (SE =0.846, P0.001), 
both being significant. Again, our estimates conveyed a 
steeper slope for the linear reduction of sleep problems over 
time in the pregabalin group.
Lastly, we obtained the estimated change in slope (and 
intercept) after discounting the effect of anxiety changes over 
time using the restricted model with covariates (Figure 3). The 
mean slope for the MOS-S trajectory for the UC group after 
adjusting for anxiety reduction was µβ =-7.598 (SE =1.233, 
P0.001), while the mean intercept for this group was 
µα =15.970 (SE =1.102, P0.001). The estimated change 
in the random slope of MOS-S change over time due to 
pregabalin treatment, as compared with UC, was γβ =-3.990 
(SE =0.863, P0.001), and the estimated impact on the 
random intercept was γα =3.973 (SE =0.794, P0.001), both 
of which were significant. The effect of anxiety values on 
MOS-S values was always significant and ranged from 1.297 
(SE =0.032) at month 3 to 1.529 (SE =0.039) at month 6.
Discussion
Mediational analysis is an approach to the study of the 
interaction of several effect variables with a target outcome. 
It has been applied to the study of the influence of symptoms 
Table 3 Maximum likelihood estimates and bootstrap standard errors in mediation analysis for sleep disturbances
Parameter Estimate Maximum likelihood Bootstrap
95% CI SE P SE SE-SE Mean Bias SE-Bias
γ11 4.314 2.25–6.03 0.964 0.001 0.932 0.022 4.291 -0.023 0.031
γ21 1.345 0.32–2.37 0.524 0.010 0.537 0.012 1.343 -0.002 0.017
β12 1.388 1.28–1.49 0.053 0.001 0.050 0.001 1.390 0.002 0.002
Abbreviations: Bias, bias for the parameter estimates; CI, confidence interval; SE, standard error; SE-Bias, bias for the standard errors; SE-SE, standard error estimates for 
the standard errors.
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Figure 3 estimated effect of pregabalin treatment on slope and intercept of MOs-s over time, with the presence of anxiety measures as covariates.
Notes: Boxes represent observed variables, and circles unobserved error variables. straight lines represent regression effects, and the values above them, raw estimated 
regression weights. curved lines represent covariances, and values above their estimate. Values above exogenous variables represent means and variances, and values above 
endogenous variables represent means. estimated mean values for the random slope (α) and intercept (β) have been labeled.
Abbreviations: anxiety0, anxiety score at baseline; anxiety3, anxiety score at month 3; anxiety6, anxiety score at month 6; MOs-s, Medical Outcomes study-sleep scale; 
sleep0, sleep score at baseline; sleep3, sleep score at month 3; sleep6, sleep score at month 6.
in perceived health in several disorders such as depression, 
anxiety, and pain,19–21,24 but there is a lack of this type of 
data assessing the effect on sleep disturbances in real-world 
conditions of care. The results of this study show that adding 
pregabalin to the UC for GAD improves sleep disturbances 
compared with when this drug is not added and the UC is 
changed or modified with other existing anxiolytics, this 
being the result of an effect that may be indicative of a dual 
mechanism: a direct treatment effect and an indirect effect 
via its anxiolytic action. The direct effect of pregabalin on 
improving sleep is an important finding, given that sleep 
disturbances are core complaints in patients suffering from 
GAD and because of the potential detrimental impact on 
sleep of many of the pharmacological agents that are cur-
rently available.8,10,12
Both UC and pregabalin treatment approaches led to a 
reduction in sleep problems over time. Pregabalin treatment 
attains a greater reduction in sleep problems after 6 months 
of treatment, a differential reduction that is attenuated after 
6 months. While the reduction in sleep problems for the 
UC group was -24.0 points, the reduction when adding 
pregabalin was -29.7 points, indicating a benefit of 5.7 points 
(23.8% more) for the pregabalin group. A similar pattern was 
obtained when assessing treatment benefits on anxiety; both 
treatment strategies led to a significant reduction in anxiety 
symptoms at month 3 and at month 6, but benefits were 
greater in the pregabalin group – an extra score reduction of 
1.5 points (10.3% more) on the HAM-A scale.
When both treatment effects were combined in a 
mediation analysis, the direct effect of pregabalin (as 
compared with UC) on sleep improvement (γ′
11
 =6.18) was 
significantly attenuated to γ′
11
 =4.31 when the reduction in 
anxiety symptoms was taken into account. The size of the 
direct effect of pregabalin on sleep problems was attenu-
ated when anxiety-mediated effect was discounted, but 
a significant 69.7% of the direct effect on sleep benefits 
remained, while the mediated effect of anxiety on sleep 
problems accounted for only 30.3% of the reduction in 
sleep problems. Bootstrap estimates of the mediation-model 
effects were not noticeably biased, and standard errors were 
similar to maximum likelihood estimates, leaving unaltered 
significance levels.
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It was also possible to show that a latent curve model 
would arrive at similar estimates on the reduction of sleep 
problems over time during the follow-up. While the 6-month 
follow-up reduction in sleep problems for the UC group 
attained a mean value of -24.7, the observed reduction in the 
pregabalin group was larger, with a mean value of -29.9. The 
estimated difference in slopes between treatment groups was 
-5.3 points steeper for the pregabalin group. Latent curve esti-
mates should be considered more accurate than those obtained 
by repeated measures ANOVA, with smaller standard errors 
(they are more efficient), and there is no need to adopt a list-
wise strategy for handling missing values, taking into account 
all available information for the three measures in time.
Once it was shown that multilevel latent curve estimates 
were similar to those obtained by traditional ANOVA meth-
ods, the effect on sleep problems of adding pregabalin to UC 
treatment was studied when controlling for anxiety reduction 
during follow-up. The mean slope for the MOS-S trajectory 
for the UC group after adjusting for anxiety reduction was 
-7.60, while the estimated change for the pregabalin group 
was -3.99 points steeper. The estimated impact on the ran-
dom intercept due to the inclusion of pregabalin treatment 
was 3.97 points, which means that pregabalin patients had a 
more severe condition (on average) at baseline. The estimated 
model showed that UC produces an effect on the reduction of 
sleep problems close to the estimated threshold for clinically 
significant differences of 7.6,38 after adjusting for anxiety 
reduction, and including pregabalin leads to a significantly 
steeper reduction in sleep problems, an increase of close to 
53% in the change over the 6-month follow-up (again after 
controlling for the effect of reduction in anxiety symptoms). 
In a similar mediation model on the effect of pregabalin on 
reduction in sleep problems, controlling for anxiety reduc-
tion, compared with placebo, Wittchen et al39 reported a 
65.9% direct effect of pregabalin on improvement in insom-
nia as compared with a 34.1% indirect effect via improvement 
in anxiety. In our study, the mediation model estimates for 
the pregabalin effect on sleep improvement accounted for 
a 69.8% direct effect and a 30.2% indirect effect through 
anxiety improvement, when compared with UC.
The results of this study show that pregabalin improves 
sleep, as the result of both a direct treatment effect and an 
indirect effect via its anxiolytic action that could be indica-
tive of a dual mechanism. As mentioned, the direct effect 
of pregabalin on improving sleep is an important finding, 
given that sleep disturbances are core complaints in patients 
suffering from GAD5,6 and because of the potential detrimen-
tal impact on sleep of many currently available drugs.8–11 
Several sleep instrumental studies have identified negative 
effects of SSRI/SNRIs, and while benzodiazepines may 
have sleep benefits, their long-term use is not recommended 
due to dependence potential.10,11 Although SSRI/SNRIs 
have shown significant efficacy in reducing depression and 
anxiety symptoms, clinical outcomes are likely to be subop-
timal for many patients with sleep disturbances.40 Clinical 
management of patients should focus on the comprehensive 
treatment of all anxiety-related symptoms. These findings are 
consistent with the hypothesis that pregabalin could have a 
primary effect of improving sleep that is independent of its 
anxiolytic or antinociceptive effect. In our mediation model, 
we hypothesized that part of the total effect of pregabalin on 
sleep disturbance is the direct result of treatment itself, not 
mediated through anxiety symptoms. Readers should inter-
pret the direct effect of treatment as that due to any factor or 
factors not studied as a mediator in the model. However, it 
is important to remember that GAD is the only psychiatric 
indication for which pregabalin is currently approved in the 
European Union.
Some limitations should be considered in this work. 
Firstly, this study was a post-hoc analysis based on an obser-
vational design; hence, variables have not been manipulated 
by the researchers, and random allocation of patients to 
treatments has not been ensured, as would be done in clinical 
trials. Also, a sample size calculation was not carried out in 
order to run this analysis. On the other hand, this analysis was 
able to show what occurs in the real world of anxiety patients 
when treated with pregabalin or UC therapies. Another limi-
tation is that the study used a patient-self-reported instrument 
for sleep disturbances instead of the most sophisticated 
examination of sleep disorders based on polysomnography 
evaluation or other types of instrumental tools. However, 
PRO tools such as the MOS-S are easy to administer and are 
probably the only viable method to use in real-life conditions 
of care, giving clinicians an opportunity to explore the health 
status, in terms of sleep quality, of their patients.
In conclusion, despite the limitations described, this 
analysis shows, for the first time, that pregabalin treatment 
was associated with a direct health benefit to sleep problems, 
in addition to those benefits deriving from the reduction in 
anxiety symptoms, when compared with the UC pharma-
cological treatment of patients with a GAD in real-world 
conditions of care. Thus, we can conclude that the effect of 
pregabalin treatment on sleep improvement compared with 
UC was mediated by a reduction in anxiety symptom levels 
and, also, a direct effect of pregabalin treatment on sleep 
improvement was experienced.
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